---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018454"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:23:47.840005+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Evofem extends Adjuvant convertible note maturity to April 2026; prepayment restricted

## Summary
- Notes become due on earliest of: 6 months after Oct 13, 2025 (April 13, 2026), change of control, or acceleration.
- No prepayment permitted before April 13, 2026 without Adjuvant's written consent.
- Amendment dated October 13, 2025 modifies the October 2020 Securities Purchase Agreement.
- Adjuvant Global Health Technology Fund holds the convertible promissory notes covered by the amendment.

## SEC filing metadata
- accession: 0001493152-25-018454
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/0001493152-25-018454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018454
- JSON: https://secwatch.observer/filing/0001493152-25-018454.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018454.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.